Welcome to our dedicated page for Telomir Pharms news (Ticker: TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharms stock.
Telomir Pharmaceuticals Inc (TELO) is a preclinical-stage biotech leader developing Telomir-1, an innovative therapy targeting cellular aging through telomere lengthening and oxidative stress management. This page provides investors and researchers with essential updates on the company’s scientific advancements, regulatory progress, and strategic initiatives.
Access authoritative reports on clinical trial developments, research collaborations, and financial updates directly tied to TELO’s mission to address age-related diseases. Our curated news collection covers key areas including preclinical study results, intellectual property milestones, and partnerships in longevity science.
Stay informed about Telomir’s pioneering work in metal ion regulation and telomere biology through verified press releases and objective analysis. Bookmark this page for real-time updates on breakthroughs in treating conditions like Alzheimer’s, diabetes, and progeria via TELO’s novel therapeutic approach.
Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical findings for its Telomir-1 drug candidate in treating aggressive prostate cancer. The study demonstrated that Telomir-1 successfully reversed epigenetic gene silencing of STAT1, a crucial tumor suppressor, outperforming both Paclitaxel and Rapamycin in PC3 xenograft models.
The drug showed superior efficacy in a 21-day oral administration trial, fully reversing STAT1 hypermethylation in a dose-dependent manner. Additionally, Telomir-1 reduced hypermethylation of TMS1, another key tumor suppressor, while maintaining a favorable safety profile by not elongating telomeres in cancerous cells.
These findings build upon previous March 2025 results where Telomir-1 reduced tumor volume by approximately 50% and eliminated chemotherapy-induced mortality when combined with Paclitaxel.
Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical results for its drug Telomir-1 in prostate cancer treatment. The study revealed that Telomir-1 reduced tumor size by approximately 50% in a prostate cancer animal model using aggressive human prostate cancer cells.
Key findings show that Telomir-1 actively suppresses cancer growth and protects against chemotherapy-induced toxicity when combined with Paclitaxel. While Paclitaxel alone showed severe toxicity with one-third mortality in test animals, no deaths occurred when combined with low-dose Telomir-1.
The study also addressed concerns about telomere-elongating drugs potentially promoting cancer, demonstrating instead that Telomir-1 exhibits anti-cancer effects while benefiting healthy cells. The company is advancing Telomir-1 across multiple indications, including age-related macular degeneration and Wilson's disease, with plans to submit an Investigational New Drug application by year-end.
FAQ
What is the current stock price of Telomir Pharms (TELO)?
What is the market cap of Telomir Pharms (TELO)?
